Fresh Tracks Therapeutics, Inc. Common Stock
FRTX
FRTX was delisted on the 18th of December, 2023.
38 hedge funds and large institutions have $14.1M invested in Fresh Tracks Therapeutics, Inc. Common Stock in 2018 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 8 increasing their positions, 7 reducing their positions, and 3 closing their positions.
233% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 3
31% more call options, than puts
Call options by funds: $63K | Put options by funds: $48K
23% more funds holding
Funds holding: 31 → 38 (+7)
14% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 7
25% less capital invested
Capital invested by funds: $18.7M → $14.1M (-$4.67M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$473K |
| 2 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
+$173K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$154K |
| 4 |
Renaissance Technologies
New York
|
+$147K |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
+$112K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$1.24M |
| 2 |
AI
Ariel Investments
Chicago,
Illinois
|
-$529K |
| 3 |
SM
Sabby Management
Miami Beach,
Florida
|
-$339K |
| 4 |
Millennium Management
New York
|
-$201K |
| 5 |
AIM
Alambic Investment Management
Belvedere,
California
|
-$31.3K |
FRTX Hedge Fund Activity: Q1 2018 in Review
38 of the 4,364 institutional investors tracked by Wall St. Rank reported a position in Fresh Tracks Therapeutics, Inc. Common Stock (FRTX) for Q1 2018, worth a combined $14.1M — down 25% from $18.7M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new FRTX positions and 3 closed out — a net gain of 7 holders — while 8 added to existing stakes and 7 trimmed.
The largest buyer was Armistice Capital, adding an estimated $473K. The largest seller was Stonepine Capital Management, exiting entirely with an estimated $1.24M sold.
- 38 institutional investors held Fresh Tracks Therapeutics, Inc. Common Stock (FRTX) as of Q1 2018, up from 31 in Q4 2017.
- Funds reported $14.1M of Fresh Tracks Therapeutics, Inc. Common Stock stock for Q1 2018, down 25% quarter-over-quarter.
- 10 funds opened new Fresh Tracks Therapeutics, Inc. Common Stock positions in Q1 2018 and 3 closed out, a net change of +7 holders.
- The largest Fresh Tracks Therapeutics, Inc. Common Stock buyer in Q1 2018 was Armistice Capital, an estimated $473K added.
- The largest Fresh Tracks Therapeutics, Inc. Common Stock seller in Q1 2018 was Stonepine Capital Management, an estimated $1.24M sold.
Based on aggregated 13F filings for Q1 2018.